Deletion of Lkb1 in renal tubular epithelial cells leads to CKD by altering metabolism

Journal of the American Society of Nephrology

Volumn 27, Issue 2, 2016, Pages 439-453

  Han, Seung Hyeok ^a,b   Malaga DIeguez, Laura ^a   Chinga, Frank ^a   Kang, Hyun Mi ^a   Tao, Jianling ^a,d   Reidy, Kimberly ^a,c   Susztak, Katalin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A OXIDASE; ADENYLATE KINASE; BETA CATENIN; CALCIUM BINDING PROTEIN; CALCIUM BINDING PROTEIN 39; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE I; CASPASE 3; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FENOFIBRATE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN BCL 2; PROTEIN KINASE LKB1; UNCLASSIFIED DRUG; UVOMORULIN; PROTEIN SERINE THREONINE KINASE; STK11 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEDIFFERENTIATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FATTY ACID OXIDATION; GENE DELETION; GLYCOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KIDNEY DISTAL TUBULE; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CHRONIC KIDNEY FAILURE; CYTOLOGY; EPITHELIUM CELL; GENETICS; KIDNEY TUBULE; METABOLISM; UROTHELIUM;

ANIMALS; EPITHELIAL CELLS; GENE DELETION; KIDNEY TUBULES; MICE; PROTEIN-SERINE-THREONINE KINASES; RENAL INSUFFICIENCY, CHRONIC; UROTHELIUM;

EID: 84970924256     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014121181     Document Type: Article

References (55)

1. Baas AF, Kuipers J, van der Wel NN, Batlle E, Koerten HK, Peters PJ, Clevers HC: Complete polarization of single intestinal epithelial cells upon activation of LKB1 by STRAD. Cell 116: 457-466, 2004
2. Lo B, Strasser G, Sagolla M, Austin CD, Junttila M, Mellman I: Lkb1 regulates organogenesis and early oncogenesis along AMPK-dependent and-independent pathways. JCell Biol 199: 1117-1130, 2012
3. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G,WarrenW, Aminoff M, Höglund P, Järvinen H, Kristo P, Pelin K, RidanpääM, Salovaara R, Toro T, BodmerW,Olschwang S,Olsen AS, Stratton MR, de la Chapelle A, Aaltonen LA: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391: 184-187, 1998
4. Jenne DE, Reimann H, Nezu J, Friedel W, Loff S, Jeschke R, Müller O, Back W, Zimmer M: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18: 38-43, 1998
5. Hemminki A, Tomlinson I, Markie D, Järvinen H, Sistonen P, Björkqvist AM, Knuutila S, Salovaara R, Bodmer W, Shibata D, de la Chapelle A, Aaltonen LA: Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat Genet 15: 87-90, 1997
6. Su JY, Erikson E, Maller JL: Cloning and characterization of a novel serine/threonine protein kinase expressed in early Xenopus embryos. J Biol Chem 271: 14430-14437, 1996
7. Kieselstein M, Herman G, Wahrman J, Voss R, Gitelson S, Feuchtwanger M, Kadar S:Mucocutaneous pigmentation and intestinal polyposis (Peutz-Jeghers syndrome) in a family of Iraqi jews with polycystic kidney disease. With a chromosome study. Isr J Med Sci 5: 81-90, 1969
8. Farquet JJ, Rousso C: [Peutz-Jeghers syndrome. Report on a case associated with pluricystic disease of the kidneys]. Schweiz Med Wochenschr 99: 1788-1792, 1969
9. Baas AF, Boudeau J, SapkotaGP,Smit L,Medema R,MorriceNA, Alessi DR,Clevers HC: Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J 22: 3062-3072, 2003
10. Boudeau J, Baas AF, Deak M, Morrice NA, Kieloch A, Schutkowski M, Prescott AR, Clevers HC, Alessi DR: MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 22: 5102-5114, 2003
11. Xie Z, Dong Y, Zhang M, Cui MZ, Cohen RA, Riek U, Neumann D, Schlattner U, Zou MH: Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells. J Biol Chem281: 6366-6375, 2006
12. Elhanati S, Kanfi Y, Varvak A, Roichman A, Carmel-Gross I, Barth S, Gibor G, Cohen HY: Multiple regulatory layers of SREBP1/2 by SIRT6. Cell Reports 4: 905-912, 2013
13. Lizcano JM, Göransson O, Toth R, Deak M, Morrice NA, Boudeau J, Hawley SA, Udd L, Mäkelä TP, Hardie DG, Alessi DR: LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, incluDing MARK/PAR-1. EMBO J 23: 833-843, 2004
14. Shackelford DB, Shaw RJ: The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575, 2009
15. Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL: Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18: 1533-1538, 2004
16. Shaw RJ, BardeesyN,Manning BD, Lopez L, KosmatkaM, DePinho RA, Cantley LC: The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99, 2004
17. Hardie DG, Alessi DR: LKB1 andAMPKand the cancer-metabolism link-ten years after. BMC Biol 11:36, 1-11, 2013
18. Hezel AF, Gurumurthy S, Granot Z, Swisa A, Chu GC, Bailey G, Dor Y, Bardeesy N,DepinhoRA: Pancreatic LKB1deletionleads toacinarpolarity defects and cystic neoplasms. Mol Cell Biol 28: 2414-2425, 2008
19. Chan KT, Asokan SB, King SJ, Bo T, Dubose ES, Liu W, Berginski ME, Simon JM, Davis IJ, Gomez SM, Sharpless NE, Bear JE: LKB1 loss in melanoma disrupts directional migration toward extracellular matrix cues. J Cell Biol 207: 299-315, 2014
20. Patel K, Foretz M, Marion A, Campbell DG, Gourlay R, Boudaba N, Tournier E, Titchenell P, Peggie M, Deak M, Wan M, Kaestner KH, GöranssonO, Viollet B,GrayNS, Birnbaum MJ, Sutherland C, Sakamoto K: The LKB1-salt-inducible kinase pathway functions as a key gluconeogenic suppressor in the liver. Nat Commun 5:4535, 1-16, 2014
21. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002
22. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776-1784, 2003
23. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004
24. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, Kalluri R: BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968, 2003
25. Zavadil J, Cermak L, Soto-Nieves N, Böttinger EP: Integration of TGFbeta/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J 23: 1155-1165, 2004
26. Bielesz B, Sirin Y, Si H, Niranjan T, Gruenwald A, Ahn S, Kato H, Pullman J, GesslerM, Haase VH, Susztak K: Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J Clin Invest 120: 4040-4054, 2010
27. Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, Park AS, Tao J, Sharma K, Pullman J, Bottinger EP, Goldberg IJ, Susztak K: Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 21: 37-46, 2015
28. Hong YA, Lim JH, Kim MY, Kim TW, Kim Y, Yang KS, Park HS, Choi SR, Chung S, Kim HW, Kim HW, Choi BS, Chang YS, Park CW: Fenofibrate improves renal lipotoxicity through activation ofAMPK-PGC-1a in db/db mice. PLoS ONE 9: e96147, 2014
29. Tran M, Tam D, Bardia A, Bhasin M, Rowe GC, Kher A, Zsengeller ZK, Akhavan-Sharif MR, Khankin EV, Saintgeniez M, David S, Burstein D, Karumanchi SA, Stillman IE, Arany Z, Parikh SM: PGC-1a promotes recovery after acute kidney injury during systemic inflammation inmice. J Clin Invest 121: 4003-4014, 2011
30. Woroniecka KI, Park AS,Mohtat D, Thomas DB, Pullman JM, Susztak K: Transcriptome analysis of human diabetic kidney disease. Diabetes 60: 2354-2369, 2011
31. Si H, Banga RS, Kapitsinou P, RamaiahM, Lawrence J, KambhampatiG, Gruenwald A, Bottinger E, Glicklich D, Tellis V, Greenstein S, Thomas DB, Pullman J, Fazzari M, Susztak K: Human and murine kidneys show gender-and species-specific gene expression differences in response to injury. PLoS ONE 4: e4802, 2009
32. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39[Suppl 1]: S43-S66, 2002
33. Boehlke C, Kotsis F, Patel V, Braeg S, Voelker H, Bredt S, Beyer T, Janusch H, Hamann C, Gödel M, Müller K, Herbst M, Hornung M, Doerken M, Köttgen M, Nitschke R, Igarashi P, Walz G, Kuehn EW: Primary cilia regulate mTORC1 activity and cell size through Lkb1. Nat Cell Biol 12: 1115-1122, 2010
34. Brooks C, Wei Q, Cho SG, Dong Z: Regulation of mitochondrial dynamics in acute kidney injury in cell culture and rodent models. J Clin Invest 119: 1275-1285, 2009
35. DuivenvoordenWC, Beatty LK, Lhotak S, Hill B,Mak I, PaulinG, Gallino D, Popovic S, Austin RC, Pinthus JH: Underexpression of tumour suppressor LKB1 in clear cell renal cell carcinoma is common and confers growth advantage in vitro and in vivo. Br J Cancer 108: 327-333, 2013
36. Abbud W, Habinowski S, Zhang JZ, Kendrew J, Elkairi FS, Kemp BE, Witters LA, Ismail-Beigi F: Stimulation of AMP-activated protein kinase (AMPK) is associated with enhancement of Glut1-mediated glucose transport. Arch Biochem Biophys 380: 347-352, 2000
37. Xi X, Han J, Zhang JZ: Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem 276: 41029-41034, 2001
38. Fryer LG, Foufelle F, Barnes K, Baldwin SA, Woods A, Carling D: Characterization of the role of the AMP-activated protein kinase in the stimulation of glucose transport in skeletalmuscle cells. BiochemJ 363: 167-174, 2002
39. Sambandam N, Lopaschuk GD: AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolismin the ischemic heart. Prog Lipid Res 42: 238-256, 2003
40. Nieth H, Schollmeyer P: Substrate-utilization of the human kidney. Nature 209: 1244-1245, 1966
41. Meyer C, Nadkarni V, Stumvoll M, Gerich J: Human kidney free fatty acid and glucose uptake: evidence for a renal glucose-fatty acid cycle. Am J Physiol 273: E650-E654, 1997
42. Jeppesen J,Maarbjerg SJ, Jordy AB, FritzenAM, Pehmøller C, Sylow L, Serup AK, Jessen N, Thorsen K, Prats C, Qvortrup K, Dyck JR, Hunter RW, Sakamoto K, Thomson DM, Schjerling P, Wojtaszewski JF, Richter EA, Kiens B: LKB1 regulates lipid oxidation during exercise independently of AMPK. Diabetes 62: 1490-1499, 2013
43. Gan B, Hu J, Jiang S, Liu Y, Sahin E, Zhuang L, Fletcher-Sananikone E, Colla S,Wang YA, Chin L, Depinho RA: Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature 468: 701-704, 2010
44. Koh HJ, Arnolds DE, Fujii N, Tran TT, Rogers MJ, Jessen N, Li Y, Liew CW, Ho RC, HirshmanMF, Kulkarni RN, Kahn CR,Goodyear LJ: Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol Cell Biol 26: 8217-8227, 2006
45. Thomson DM, Hancock CR, Evanson BG, Kenney SG, Malan BB, Mongillo AD, Brown JD, Hepworth S, Fillmore N, Parcell AC, Kooyman DL, Winder WW: Skeletal muscle dysfunction in muscle-specific LKB1 knockout mice. J Appl Physiol (1985) 108:1775-1785, 2010.
46. van der Velden YU,Wang L, Zevenhoven J, van Rooijen E, van Lohuizen M, Giles RH, Clevers H, Haramis AP: The serine-threonine kinase LKB1 is essential for survival under energetic stress in zebrafish. Proc Natl Acad Sci U S A 108: 4358-4363, 2011
47. Gurumurthy S, Xie SZ, Alagesan B, Kim J, Yusuf RZ, Saez B, Tzatsos A, Ozsolak F, Milos P, Ferrari F, Park PJ, Shirihai OS, Scadden DT, Bardeesy N: The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature 468: 659-663, 2010
48. Dugan LL, You YH, Ali SS, Diamond-Stanic M, Miyamoto S, DeCleves AE, Andreyev A,Quach T, Ly S, Shekhtman G, NguyenW, Chepetan A, Le TP, Wang L, Xu M, Paik KP, Fogo A, Viollet B, Murphy A, Brosius F, Naviaux RK, Sharma K:AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest 123: 4888-4899, 2013
49. Satriano J, Sharma K, Blantz RC, Deng A: Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease. Am J Physiol Renal Physiol 305: F727-F733, 2013
50. Portilla D, Dai G, McClure T, Bates L, Kurten R, Megyesi J, Price P, Li S: Alterations of PPARalpha and its coactivator PGC-1 in cisplatin-induced acute renal failure. Kidney Int 62: 1208-1218, 2002
51. Li S,Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, Portilla D: PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 286: F572-F580, 2004
52. Gomez IG, MacKenna DA, Johnson BG, Kaimal V, Roach AM, Ren S, NakagawaN, Xin C,Newitt R, Pandya S, Xia TH, Liu X, BorzaDB,Grafals M, Shankland SJ, Himmelfarb J, Portilla D, Liu S, Chau BN, Duffield JS: Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest 125: 141-156, 2015
53. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR, DePinho RA: Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419: 162-167, 2002
54. Shao X, Somlo S, Igarashi P: Epithelial-specific Cre/lox recombination in the developing kidney and genitourinary tract. JAmSocNephrol 13: 1837-1846, 2002
55. Mehlem A, Hagberg CE, Muhl L, Eriksson U, Falkevall A: Imaging of neutral lipids by oil red O for analyzing the metabolic status in health and disease. Nat Protoc 8: 1149-1154, 2013